These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34857535)

  • 1. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.
    Nowak RJ; Coffey CS; Goldstein JM; Dimachkie MM; Benatar M; Kissel JT; Wolfe GI; Burns TM; Freimer ML; Nations S; Granit V; Smith AG; Richman DP; Ciafaloni E; Al-Lozi MT; Sams LA; Quan D; Ubogu E; Pearson B; Sharma A; Yankey JW; Uribe L; Shy M; Amato AA; Conwit R; O'Connor KC; Hafler DA; Cudkowicz ME; Barohn RJ;
    Neurology; 2022 Jan; 98(4):e376-e389. PubMed ID: 34857535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
    Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
    JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.
    Piehl F; Eriksson-Dufva A; Budzianowska A; Feresiadou A; Hansson W; Hietala MA; Håkansson I; Johansson R; Jons D; Kmezic I; Lindberg C; Lindh J; Lundin F; Nygren I; Punga AR; Press R; Samuelsson K; Sundström P; Wickberg O; Brauner S; Frisell T
    JAMA Neurol; 2022 Nov; 79(11):1105-1112. PubMed ID: 36121672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.
    Bi Z; Zhan J; Zhang Q; Gao H; Yang M; Ge H; Gui M; Lin J; Bu B
    Front Immunol; 2023; 14():1177249. PubMed ID: 37266422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Howard JF; Bresch S; Genge A; Hewamadduma C; Hinton J; Hussain Y; Juntas-Morales R; Kaminski HJ; Maniaol A; Mantegazza R; Masuda M; Sivakumar K; Śmiłowski M; Utsugisawa K; Vu T; Weiss MD; Zajda M; Boroojerdi B; Brock M; de la Borderie G; Duda PW; Lowcock R; Vanderkelen M; Leite MI;
    Lancet Neurol; 2023 May; 22(5):395-406. PubMed ID: 37059508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.
    Di L; Shen F; Wen X; Lu Y; Zhu W; Wang M; Da Y
    Front Immunol; 2022; 13():839075. PubMed ID: 35371086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
    Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
    Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ravulizumab: A Review in Generalised Myasthenia Gravis.
    Kang C
    Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Pasnoor M; He J; Herbelin L; Burns TM; Nations S; Bril V; Wang AK; Elsheikh BH; Kissel JT; Saperstein D; Shaibani JA; Jackson C; Swenson A; Howard JF; Goyal N; David W; Wicklund M; Pulley M; Becker M; Mozaffar T; Benatar M; Pazcuzzi R; Simpson E; Rosenfeld J; Dimachkie MM; Statland JM; Barohn RJ;
    Neurology; 2016 Jul; 87(1):57-64. PubMed ID: 27306628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
    Siddiqi ZA; Nowak RJ; Mozaffar T; O'Brien F; Yountz M; Patti F;
    Muscle Nerve; 2021 Dec; 64(6):662-669. PubMed ID: 34590717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.
    Sanders DB; Hart IK; Mantegazza R; Shukla SS; Siddiqi ZA; De Baets MH; Melms A; Nicolle MW; Solomons N; Richman DP
    Neurology; 2008 Aug; 71(6):400-6. PubMed ID: 18434638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis.
    Bril V; Szczudlik A; Vaitkus A; Rozsa C; Kostera-Pruszczyk A; Hon P; Bednarik J; Tyblova M; Köhler W; Toomsoo T; Nowak RJ; Mozaffar T; Freimer ML; Nicolle MW; Magnus T; Pulley MT; Rivner M; Dimachkie MM; Distad BJ; Pascuzzi RM; Babiar D; Lin J; Querolt Coll M; Griffin R; Mondou E
    Neurology; 2023 Feb; 100(7):e671-e682. PubMed ID: 36270895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.
    Du Y; Li C; Hao YF; Zhao C; Yan Q; Yao D; Li L; Zhang W
    J Neurol; 2022 Aug; 269(8):4229-4240. PubMed ID: 35243555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.
    Lu J; Zhong H; Jing S; Wang L; Xi J; Lu J; Zhou L; Zhao C
    Muscle Nerve; 2020 Mar; 61(3):311-315. PubMed ID: 31875994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
    Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
    Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes.
    Kefalopoulou ZM; Veltsista D; Germeni A; Lykouras D; Tsiamaki E; Chroni E
    Neurol Sci; 2024 Mar; 45(3):1233-1242. PubMed ID: 37831214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.